• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Transportation

Cramer: When a Trump Tweet Is a Buy Signal

Drug companies are the latest targets/beneficiaries.
By JIM CRAMER Mar 07, 2017 | 02:00 PM EST
Stocks quotes in this article: LLY, REGN, AMGN, BA, LMT, GM, MRK, PFE, AGN, MYL

These stocks are red hot. They are levitating. It's the best group out there. And then you get the tweet, the presidential tweet that wrecks everything. Or does it?

We came in today not expecting much of the session. We have little news, few earnings, it's almost placid. Then we got the lightning bolt from @realDonaldTrump: "I am working on a new system where there will be competition in the drug industry. Pricing for the American people will come way down."

What do you do? Do you:

  1. Panic and sell everything?
  2. Wait to see what happens?
  3. Buy the selloff?

The answer, drum roll please ... C, you buy the weakness.

Why would you take the other side of the trade of the president of the United States of America?

First, this isn't the first time he has trashed the industry. He campaigned against the drug companies hard in the winter and spring of last year and then he reiterated that view in his Man of the Year interview for Time Magazine.

Second, the drug companies are incredibly powerful in Washington. They have systematically frustrated any attempts by the government to restrain pricing. Only a single-payer system where the government mandates pricing and drug makers have no choice but to bow down or be kicked out of the Medicare system can truly provide lower prices. If there were two drugs, the government could pit them against each other and buy the one with the lower offer and cut the other out. In that sense, the government would basically be determining prices.

This has long been a dream of some of the most powerful Democrats and one that the Republicans have called an anathema to everything they believe in. This is not a deregulation issue. It is congressional and I am telling you right now that Trump will not have his way on this issue. One of the biggest losers would be Eli Lilly (LLY) and I simply do not believe the former governor of Indiana who is so close to the company, Vice President Pence, would just sit there and let this happen, either. It's almost inconceivable. Yes, when there are two drugs that seem very similar, like Regeneron's (REGN) anti-cholesterol drug and Amgen's (AMGN) similar drug, then there could be a negotiated price. But those are actually quite rare these days.

So why buy them? Because every time the president has singled out an industry or a company to make a deal, the sector and the single stock get hammered and you have to hold your nose and buy.

You disagree? Look at Boeing (BA) . Thirty points ago, Trump laid into the maker of Air Force One. That was your last chance to buy. The president's riposte against Lockheed Martin (LMT) gave you a dip that allowed you to get a $19 point gain. The president brought General Motors (GM) stock down to $34 over the Chevy Cruze fracas. What a terrific buy that was. (Lockheed Martin is part of TheStreet's Dividend Stock Advisor portfolio.) 

I am not being glib about this. It's just that it's a lot harder for the president to negotiate a whole system of prices than it is to berate an individual company because Congress is such a great defender of so many companies that feed at the trough of the feds. Anyone who remembers the fights Bill Clinton had against the drug companies, the fights that so many Democratic members of Congress have had against higher prices, knows these battles can't be won.

And maybe they shouldn't be. Our drug industry is by far the best in the world. If I were the president, I would be going after other countries for routinely ripping off our drug companies by jamming them with lower prices, which causes them to charge more here.

You want to lower drug prices here? You go after every country that squeezes the profits out of our companies knowing that there's no cost to it because those companies make them in the U.S. It's the classic case of our trading partners screwing us with no president ever standing up for our interests. That's how you would get prices down.

Regardless, what matters the most is that this group has been red hot and there's been no chance to get in at any price break. They have been horses and it's been impossible to get on them. I like Merck (MRK) for its Keytruda anti-cancer franchise. Lilly's got a fabulous diabetes pipeline. Pfizer's (PFE) willing to bring out value with some self-help. Allergan's (AGN) the cheapest large-capitalization growth company of all, one that has been pancaked because of its failed merger with Pfizer and hasn't gotten anywhere near back to where it was even as its earnings estimates are moving up. And if you want competition, the company that can create the most competition is Mylan Labs (MYL) , which sells at 7x next year's earnings. You really fear that the president finds a way to create competition? Go with Mylan. (Allergan is part of TheStreet's Action Alerts PLUS portfolio.) 

I am not dissing the president here. I think he's right to try to get drug prices down. I am just suggesting a better way, which is to go after the free riders around the globe in return for lower prices here.

Once again, I want to explain that you don't buy stocks because of anything that the president needs Congress for. While I totally agree that with Republican majorities in both houses, the president should be able to get his way. But we don't know what his way is. Are we going to have a border tax knowing that it is going to jack up the prices of retail goods, hurting his constituency in a disproportionate way? Is that what he's going to check off on? But without some offsetting tax, there is no way he is going to negotiate lower tax rates. Many of the Republicans have sworn they will do nothing to raise the debt ceiling. Are these people who are willing to cut taxes to make it even less likely we balance the budget?

Do we think that repealing and replacing something as complicated as the health care system, which took forever to design, will just sail through? We don't even know what's sailing, for heaven's sakes. The stocks that are going up in health care, everything from the insurers to the hospitals to the critical-care facilities, can't all be right. If there's a real compromise, there will be real losers. Right now, the stocks are saying there won't be any.

My take is that the only real power the president has at this moment is to deregulate, and he's using that power with a vengeance whether it be for autos or airlines or banks or oil companies. It's all coming together for these companies and they are going to stay winners.

I prefer to keep finding companies that are fitting broad themes, including those levered to worldwide growth. But if I can find some stocks I like but have roared higher and they get dinged by some tweets, which often produce strong gains down the road for their targets? Count me in. Count me as a buyer.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Action Alerts PLUS, which Cramer co-manages as a charitable trust, is long AGN.

TAGS: Investing | U.S. Equity | Transportation | Healthcare | Jim Cramer | Markets | Politics | Stocks

More from Transportation

Old Dominion Freight Line Is Ready to Roll Again

Bruce Kamich
Jun 28, 2022 11:15 AM EDT

Here's what traders could do now.

Southwest Airlines Upgraded But the Charts Didn't Get the Memo

Bruce Kamich
Jun 23, 2022 1:35 PM EDT

Let's take a look.

Will FedEx Deliver? Checking the Charts Ahead of Earnings

Bruce Kamich
Jun 23, 2022 12:17 PM EDT

Here's our plan.

Winnebago's Numbers Were Awesome: Here's How to Go Along for the Ride

Stephen Guilfoyle
Jun 22, 2022 11:00 AM EDT

Here's my trading strategy for investors right now.

Why It Costs $1B Per Year to Go Up Against Indonesia's GoTo Group

Alex Frew McMillan
Jun 22, 2022 6:30 AM EDT

It's not often you find a tech stock with defensive characteristics and a strong upside, but GoTo offers both.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 07:34 AM EDT PAUL PRICE

    A $525,000 Vote of Confidence on Macerich (MAC)

  • 09:49 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    Stop Wishing, Hoping, and Praying and Take Control...
  • 07:59 PM EDT PAUL PRICE

    Very Good Quarterly Numbers From Bassett Furniture (BSET)

    Bassett Furniture blew right through analysts es...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login